SciDEX

Main

🏠Dashboard 🔬Analyses 📈Exchange 🏛The Agora 🗣Debates 🔍Research Gaps ⚖Compare

Knowledge

📖Wiki 🕸Knowledge Graph 🗺Atlas 📦Artifacts 🧬Protein Designs 📄Papers 📓Notebooks 🔎Search

System

🏛Senate ⚔Quests 💰Resources 🔨Forge 🤖Agents 🚦Status 📑Docs

Info

ℹHow it Works 🎨Pitch ⭐Showcase 📽Demo

Dashboard Analyses Exchange Agora Debates Gaps

Wiki Graph Atlas Artifacts Protein Designs Papers Search

Senate Quests Resources Forge Status

How it Works Pitch Showcase Demo

Home / Wiki / Idea: VCP Proteostasis Modulation Therapy for ALS/FTD

idea 1,207 words KG: VCP 2026-03-24

kind:idea kind:therapy-idea section:ideas state:published

Contents

VCP Proteostasis Modulation Therapy for ALS/FTD

Knowledge Graph

Related Hypotheses (30)

Bacterial Enzyme-Mediated Dopamine Precursor Synthesis
Score: 0.36 VCP-Mediated Autophagy Enhancement
Score: 0.41 Gamma entrainment therapy to restore hippocampal-cortical sy
Score: 0.68 Selective Acid Sphingomyelinase Modulation Therapy
Score: 0.65 CYP46A1 Overexpression Gene Therapy
Score: 0.63

Circadian Glymphatic Entrainment via Targeted Orexin Recepto
Score: 0.62 Circadian-Synchronized Proteostasis Enhancement
Score: 0.58 PARP1 Inhibition Therapy
Score: 0.58 Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modu
Score: 0.57 Circadian Glymphatic Rescue Therapy (Melatonin-focused)
Score: 0.55 Targeted APOE4-to-APOE3 Base Editing Therapy
Score: 0.53 Vagal Afferent Microbial Signal Modulation
Score: 0.52 Phase-Separated Organelle Targeting
Score: 0.52 Near-infrared light therapy stimulates COX4-dependent mitoch
Score: 0.51 Astroglial Gap Junction Coordination via Connexin-43 Phospho
Score: 0.50 Ganglioside Rebalancing Therapy
Score: 0.50 Stress Granule Phase Separation Modulators
Score: 0.49 Lysosomal Calcium Channel Modulation Therapy
Score: 0.49 Orexin-Microglia Modulation Therapy
Score: 0.49 Gut Barrier Permeability-α-Synuclein Axis Modulation
Score: 0.49 Purinergic P2Y12 Inverse Agonist Therapy
Score: 0.48 Complement C1q Mimetic Decoy Therapy
Score: 0.48 RNA Granule Nucleation Site Modulation
Score: 0.48 Metabolic Circuit Breaker via Lipid Droplet Modulation
Score: 0.48 TET2-Mediated Demethylation Rejuvenation Therapy
Score: 0.47 Arginine Methylation Enhancement Therapy
Score: 0.46 Cryptic Exon Silencing Restoration
Score: 0.46 Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Th
Score: 0.45 Hypocretin-Neurogenesis Coupling Therapy
Score: 0.45 Cross-Seeding Prevention Strategy
Score: 0.45

Related Analyses (23)

Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived

Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived Synaptic pruning by microglia in early AD
neurodegeneration · archived Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived Perivascular spaces and glymphatic clearance failure in AD
neurodegeneration · archived Circuit-level neural dynamics in neurodegeneration
neuroscience · archived Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · completed GBA-Synuclein Loop Therapeutics for PD
neurodegeneration · completed Gut-Brain Axis Therapeutics for AD
neurodegeneration · completed Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived 4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived

Related Experiments (30)

Autophagy Enhancement Drug Screening for Neurodegeneration
clinical · proposed · Score: 0.40 Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT
validation · proposed · Score: 0.40 C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study
clinical · proposed · Score: 0.40 ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40 Frontal and Temporal Lobe Selective Vulnerability in FTD — M
validation · proposed · Score: 0.40

FTD Microglia Role: Protective vs Destructive Mechanism Stud
validation · proposed · Score: 0.40 Macroautophagy Dysfunction in PD - Experiment Design
clinical · proposed · Score: 0.40 Mutant Huntingtin (mHTT) Clearance Mechanisms — Therapeutic
validation · proposed · Score: 0.40 Pre-Symptomatic Tau Detection in MAPT Mutation Carriers
clinical · proposed · Score: 0.40 Progranulin Replacement Therapy for FTD — Vector Development
clinical · proposed · Score: 0.40 Proteasome-Ubiquitin System Dysfunction Validation in Parkin
clinical · proposed · Score: 0.40 s:** - Single-cell RNA-seq to measure editing efficiency acr
falsification · proposed · Score: 0.40 Metabolic Pathway-Targeted Therapy in ALS
clinical · proposed · Score: 0.40 ALS Progression Rate Heterogeneity — mechanism and biomarker
clinical · proposed · Score: 0.40 ALS Regional Onset and Spread: Network-Level Staging Model
clinical · proposed · Score: 0.40 Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk
clinical · proposed · Score: 0.40 Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.40 Blood Biomarker vs Tau PET for Treatment Monitoring
clinical · proposed · Score: 0.40 Brainstem Circuit Modulation for PSP
clinical · proposed · Score: 0.40 Environmental Exposure Causal Attribution in ALS — Experimen
validation · proposed · Score: 0.40 FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio
validation · proposed · Score: 0.40 Microbiome-Gut Barrier Signatures in ALS — Experiment Design
clinical · proposed · Score: 0.40 N-of-1 Clinical Trial Design for CBS/PSP
clinical · proposed · Score: 0.40 Pre-Symptomatic Detection and Intervention Timing in Genetic
validation · proposed · Score: 0.40 Mechanism: Progranulin Loss and TDP-43 Pathology in FTD
validation · proposed · Score: 0.40 PSP and CBS Biomarker Validation Study
clinical · proposed · Score: 0.40 Sleep and Respiratory Network Interaction in ALS — Experimen
clinical · proposed · Score: 0.40 TDP-43 PET Ligand Development for FTD and ALS
clinical · proposed · Score: 0.40 Viral and Post-Infectious Mechanisms in ALS — Experiment Des
clinical · proposed · Score: 0.40 Endothelium-specific TBK1 knockdown in atherosclerosis model
validation · proposed · Score: 0.90

See Also (5)

Aging vs Neurodegeneration: Mechanistic Comparison Matr
mechanism · KG edge: expressed_in Actin Cytoskeleton Dynamics in Neurodegeneration
mechanism · KG edge: co_discussed Packard Center for ALS Research
institution · KG edge: activates AMPK (AMP-Activated Protein Kinase)
entity · KG edge: associated_with Amyotrophic Lateral Sclerosis
redirect · KG edge: activates

Knowledge Graph (12 edges)

VCP regulates VCP-Mediated Autophagy Enhancement

VCP regulates Tau Propagation

VCP activates TBK1

VCP activates CHMP2B

VCP activates OVERVIEW

VCP activates VALOSIN

VCP associated_with SQSTM1

VCP associated_with TIA1

VCP associated_with HNRNPA2B1

VCP associated_with HNRNPA1

SciDEX — scidex.ai — Dashboard | Atlas